Certara
its Simcyp Simulator, a PBPK platform built over 25 years with a consortium of more than 35 pharmaceutical companies, released Version 25 in early 2026 building on EMA qualification, and Certara reported that Simcyp simulation results replaced ten human trials for the chronic myeloid leukemia therapy asciminib.
- Country
- United States
- Ticker
- CERT
EMA qualified
PBPK modeling
us
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| bioinformatics-omics | ✓ | ✓ | ✓ | ✓ |
| regenerative-personalized | ✓ | ✓ | — | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Patient digital twins & in-silico trials | regenerative-personalized | Medium | → |
| Toxics screening (toxicomics, service) | bioinformatics-omics | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.